This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Modena, P. Articles by Sozzi, G. Search for Related Content PubMed PubMed Citation Articles by Modena, P. Articles by Sozzi, G.

SMARCB1/INI1 Tumor Suppressor Gene Is Frequently Inactivated in Epithelioid Sarcomas

Units of ¹ Molecular Cytogenetics and ² Molecular Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy; and ³ Department of Genetics, Portuguese Oncology Institute, Porto, Portugal

Requests for reprints: Gabriella Sozzi, Molecular Cytogenetics Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, via Venezian 1, 20133 Milano, Italy. Phone: 39-02-23902232; Fax: 39-02-23902764; E-mail: gabriella.sozzi{at}istitutotumori.mi.it.

Epithelioid sarcoma is a rare soft tissue neoplasm of uncertain lineage that usually arises in the distal extremities of adults, presents a high rate of recurrences and metastases and frequently poses diagnostic dilemmas. The recently reported large-cell "proximal-type" variant is characterized by increased aggressiveness, deep location, preferential occurrence in proximal/axial regions of older patients, and rhabdoid features. Previous cytogenetic studies indicated that the most frequent alterations associated with this tumor entity affect chromosome 22. In this study, combined spectral karyotyping, fluorescence in situ hybridization, and array-based comparative genomic hybridization analyses of two proximal-type cases harboring a rearrangement involving 10q26 and 22q11 revealed that the 22q11 breakpoints were located in a 150-kb region containing the SMARCB1/INI1 gene, and that homozygous deletion of the gene was present in the tumor tissue. The SMARCB1/INI1 gene encodes for an invariant subunit of SWI/SNF chromatin remodeling complex and has been previously reported to act as a tumor suppressor gene frequently inactivated in infantile malignant rhabdoid tumors. We analyzed SMARCB1/INI1 gene status in nine additional epithelioid sarcoma cases (four proximal types and five conventional types) and altogether we identified deletions of SMARCB1/INI1 gene in 5 of 11 cases, all proximal types. We confirmed and further extended the number of cases with SMARCB1/INI1 inactivation to 6 of 11 cases, by real-time quantitative PCR analysis of mRNA expression and by SMARCB1/INI1 immunohistochemistry. Overall, these results point to SMARCB1/INI1 gene involvement in the genesis and/or progression of epithelioid sarcomas. Analysis of larger series of epithelioid sarcomas will be necessary to highlight putative clinically relevant features related to SMARCB1/INI1 inactivation.

This article has been cited by other articles:

				E. S. McKenna, C. G. Sansam, Y.-J. Cho, H. Greulich, J. A. Evans, C. S. Thom, L. A. Moreau, J. A. Biegel, S. L. Pomeroy, and C. W. M. Roberts Loss of the Epigenetic Tumor Suppressor SNF5 Leads to Cancer without Genomic Instability Mol. Cell. Biol., October 15, 2008; 28(20): 6223 - 6233. [Abstract] [Full Text] [PDF]

				A. Varshavsky From the Cover: Targeting the absence: Homozygous DNA deletions as immutable signposts for cancer therapy PNAS, September 18, 2007; 104(38): 14935 - 14940. [Abstract] [Full Text] [PDF]